Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder (Q34114364)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

0 references

multicenter clinical trial

0 references

placebo-controlled trial

1 reference

based on heuristic

inferred from title

generalized anxiety disorder

1 reference

based on heuristic

inferred from title

object named as

Howard H Feldman

2

0 references

author name string

Vladimir Coric

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Dan A Oren

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Anantha Shekhar

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Joseph Pultz

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Randy C Dockens

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Xiaoling Wu

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Kimberly A Gentile

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Shu-Pang Huang

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Eileen Emison

10

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Terrye Delmonte

11

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Bernadette B D'Souza

12

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Daniel L Zimbroff

13

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Jack A Grebb

14

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Andrew W Goddard

15

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Elyse G Stock

16

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Depression and Anxiety

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

417-425

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Clinical practice. Generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Human and economic burden of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Protective and damaging effects of stress mediators

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Acute stress potentiates anxiety in humans

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Stress burden and the lifetime incidence of psychiatric disorder in young adults: racial and ethnic contrasts

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Characterization of a 41-Residue Ovine Hypothalamic Peptide That Stimulates Secretion of Corticotropin and β-Endorphin

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Role of corticotropin releasing factor in anxiety disorders: a translational research perspective

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

The role of the HPA axis in psychiatric disorders and CRF antagonists as potential treatments.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Major Depressive Disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

CRH-sub-1 receptor antagonists for the treatment of depression and anxiety

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

The assessment of anxiety states by rating

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Innovative approaches for the treatment of depression: targeting the HPA axis

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Role of CRF(1) and CRF(2) receptors in fear and anxiety

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Corticotrophin releasing factor-induced synaptic plasticity in the amygdala translates stress into emotional disorders.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Plexin/neuropilin complexes mediate repulsion by the axonal guidance signal semaphorin 3A.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Knowing how to navigate: mechanisms of semaphorin signaling in the nervous system

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

To move or not to move? Semaphorin signalling in cell migration

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Semaphorins as mediators of neuronal apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Anxiety and comorbid measures associated with PLXNA2.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

Identification of the semaphorin receptor PLXNA2 as a candidate for susceptibility to schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

21 January 2018

The measurement of disability.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20695

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DA.20695

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34114364&oldid=1993744004"